Sébastien Papot

Sébastien Papot

Auto-generated profile, based on publicly available information

Sébastien Papot

University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Equipe Labellisée Ligue Contre le Cancer, 4 Rue Michel-Brunet, TSA 51106, 86073 Poitiers Cedex 9, France

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2015 in Chemical Science
Verified
Journal Article
Open access
PDF file
RBRomain Barat
Romain Barat
TLThibaut Legigan
Thibaut Legigan
ITIsabelle Tranoy-Opalinski
Isabelle Tranoy-Opalinski
BRBrigitte Renoux
Brigitte Renoux
EPElodie Péraudeau
Elodie Péraudeau
SPSébastien Papot
Sébastien Papot
The development of mechanically interlocked molecular systems programmed to operate autonomously in biological environments is an emerging field of research with potential medicinal applications. Within this framework, functional rotaxane- and pseudorotaxane-based architectures are starting to attract interest for the delivery of anticancer drugs, with the ultimate goal to improve the efficiency of cancer chemotherapy. Here, we report an enzyme-sensitive [2]-rotaxane designed to release a potent anticancer drug within tumor cells. The molecular device includes a protective ring that prevents the premature liberation of the drug in plasma. However, once located inside cancer cells the [2]-rotaxane leads to the release of the drug through the controlled disassembly of the mechanically interlocked components, in response to a determined sequence of two distinct enzymatic activations. Furthermore, in vitro biological evaluations reveal that this biocompatible functional system exhibits a noticeable level of selectivity for cancer cells overexpressing β-galactosidase.

12 August 2009 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
AFAntony Fernandes
Antony Fernandes
AVAurélien Viterisi
Aurélien Viterisi
FCFrédéric Coutrot
Frédéric Coutrot
SPStéphanie Potok
Stéphanie Potok
DLDavid A. Leigh
David A. Leigh
SPSébastien Papot
Sébastien Papot

8 March 2017 in Chemical Science
Verified
Journal Article
Open access
PDF file
BRBrigitte Renoux
Brigitte Renoux
FRFlorian Raes
Florian Raes
TLThibaut Legigan
Thibaut Legigan
EPElodie Péraudeau
Elodie Péraudeau
BEBalkis Eddhif
Balkis Eddhif
SPSébastien Papot
Sébastien Papot
A drug delivery system targeting the tumour microenvironment produces outstanding therapeutic efficacy on triple-negative mammary and pancreatic models.

1 March 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ITIsabelle Tranoy-Opalinski
Isabelle Tranoy-Opalinski
TLThibaut Legigan
Thibaut Legigan
RBRomain Barat
Romain Barat
JCJonathan CLARHAUT
Jonathan CLARHAUT
MTMikaël Thomas
Mikaël Thomas
SPSébastien Papot
Sébastien Papot

20 September 2012 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
TLThibaut Legigan
Thibaut Legigan
JCJonathan CLARHAUT
Jonathan CLARHAUT
ITIsabelle Tranoy‐Opalinski
Isabelle Tranoy‐Opalinski
AMArnaud Monvoisin
Arnaud Monvoisin
BRBrigitte Renoux
Brigitte Renoux
SPSébastien Papot
Sébastien Papot

6 March 2019 in Chemical Science
Verified
Journal Article
Open access
PDF file
WVWarren Viricel
Warren Viricel
GFGuy Fournet
Guy Fournet
SBSabine Beaumel
Sabine Beaumel
EPEmeline Perrial
Emeline Perrial
SPSébastien Papot
Sébastien Papot
BJBenoît Joseph
Benoît Joseph
Antibody-drug conjugates (ADCs) convey highly potent anticancer drugs to antigen-expressing tumor cells, thereby sparing healthy tissues throughout the body. Pharmacokinetics and tolerability of ADCs are predominantly influenced by the drug-antibody ratio (DAR) of the conjugates, which is to-date limited to a value of 3–4 drugs per antibody in ADCs under clinical investigations. Here, we report the synthesis of monodisperse (i.e. discrete) polysarcosine compounds and their use as a hydrophobicity masking entity for the construction of highly-loaded homogeneous β-glucuronidase-responsive antibody-drug conjugates (ADCs). The highly hydrophilic drug-linker platform described herein improves drug-loading, physicochemical properties, pharmacokinetics and in vivo antitumor efficacy of the resulting conjugates.